Crystal Genomics to commence dosing in Phase 3 studies of CG100649 for osteoporosis

Published: 2013-10-28 06:56:00
Updated: 2013-10-28 06:56:00
Crystal Genomics (CG) said Thursday it will commence dosing in Phase 3 clinical trials of CG100649, a next-generation non-steroidal anti-inflammatory drug (NSAID) for the treatment of osteoporosis (OA).

The current Phase 3 studies will be conducted in 350 OA patients at 14 local university hos...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.